Interlink Electronics, Inc. (LINK)
Live price chart, market sentiment, and community perspectives for Interlink Electronics, Inc. (NASDAQ: LINK).
Live price chart, market sentiment, and community perspectives for Interlink Electronics, Inc. (NASDAQ: LINK).
On our desk, Interlink Electronics (LINK) presents a classic micro-cap dichotomy. On one side, you have genuine operational progress—returning to profitability in Q2 2026 and securing a spot in the Russell Microcap Index. On the other side, the market punished the stock by 15% back in May upon announcing the financing plans for their non-binding acquisition target that pulls in $33 million in revenue. Institutional sentiment is cautiously optimistic given the $8.67 analyst price target, but liquidity remains thin with daily volumes often hovering around 20k shares. If you are sizing positions here, you have to respect the volatility tied to their aggressive MandA pipeline.
Watching the technical charts and order flow for LINK, the risk profile is heavily tied to execution and macro headwinds. StockInvest.us rates it as a Hold/Accumulate with a low technical score, pointing out sell signals from recent pivot tops and low overall volume that amplifies downside risk. Furthermore, looking at the risk disclosures, the success of their growth strategy depends entirely on closing conditions for the pending acquisition, avoiding severe integration snags, and maintaining raw material availability. With a Piotroski F-Score sitting at 3/9, fundamental risk management requires keeping a close eye on cash burn and dilution terms.
From a quantitative evaluation perspective, analyzing LINK requires looking closely at how they structure the equity pricing for their potential $33M-revenue target. Management outlined valuation parameters using Interlink’s prevailing market price within a $5.00 to $10.00 range. When interviewing management or reviewing their LD Micro and Lytham Partners presentation transcripts, analysts should press hard on the exact debt-versus-equity mix for the transaction financing to gauge potential per-share dilution. Their stated ambition of hitting $100 million in revenue in a few years is compelling for a company currently posting trailing revenues around $12.6 million, but the bridge from here to there relies completely on flawless MandA execution.
Explore plasma cleansing, somatic organ swaps, and BCI.